call payers, clinical for highlights initiation on to study will Kamal, results. CFO, you and our details joining of newly published the the financial discuss business CAPSTONE over our QX then RADR Today, our our thank call. the everyone I to and TiGER hand I'll study Ryan, pipeline, Thanks, give for platform. experience updates on and our the
saw X,XXX record we AVISE of AVISE for appreciate eighth tests. In XX,XXX had approximately a health we again, As and at rate total high providers XXX retention flagship delivered the providers quarter quarter. the XX,XXX among and record in the care Lupus record of a a We sixth quarter tests as the a Exagen. record quarter a in delivered CTD always, your providers. adopting row This a tests adopters, prior CTD health we the in of record Once as a care our have for set achieved ordering least care and second ordering XX% year-to-date. AVISE a XX% quarter AVISE the of quarter new a of a eighth of continued setting with XXXX, that health well for record row and stickiness CTD from of we for marks row support adopters
provide these achievements, April with brands effective our pleased CMS We be demonstrate per all uncertain, and for our our PLA are the XXXX, maintaining a consistent can time-consuming. obtaining new Xst, for recognize physicians. we code which for The protein-based patients MAC reimbursement Last PLA quarter, this to value and that disclosed test. lengthy AVISE Noridian, priced code $X,XXX at process tests Lupus. and test agreed
AVISE ended X,XXX Part our Noridian we Medicare to B During the Lupus. for code reimbursement XXth, quarter June claims PLA submitted under for XXXX,
AVISE information, to not determination claims with received, records. to Medicare that coverage or order The those submitted coverage, code of of Having Noridian is As for a denied and to provider. from been under PLA of of claims additional have or third-party formal August X,XXX Xst, Noridian reimbursement claims pricing pending the with with such been test requests have our from coverage a price other medical confirm determination. request synonymous a claims new particular as the PLA XXX subject no does XX paid, these any test remain code. are response secure balance associated any for In Lupus we for code a for coverage PLA not
resolved, aggregate Lupus a anticipate Lupus revenue of Medicare million. unpaid interruption AVISE our we We reimbursement QX from have significant claims not response. to this received yet approximately with Until amount seeking our respect to issue claims. we a are for from is The reimbursement $X Medicare AVISE is
resolution provide test, our the Medicare total and to addressing. open XXst, Medicare for the understand all. can All a request is volumes resolved, at which better approximately of on AVISE achieved beneficiaries. basis additional period under Lupus cannot we the will XX% CTD information, for including we no context XXXX, such or process March review, Xst, our the being definitively until are To either of Medicare claims April these subject claims, AVISE orders Medicare uncertainty the Lupus assurance unpaid timely recognize uncertainty in related the for outcome Lupus, XXXX, to AVISE of be claims to any in Due are to we of of were for appealed or that AVISE revenue
the For approximately Medicare, our CTD, XX% same averaged Lupus including for AVISE of for revenue period, our AVISE has recognized total revenue.
in done national past, working we the also will commercial continue managed maintain obtain for care brands. to with AVISE have we coverage and plans As
study for study effective, tens Lupus and ANA & AVISE study, Managed approach, and test of hundreds cost those of tested the to the as This CAPSTONE will SLE the road it laboratory study for are opposed receiving clinically test greater costs of lower for initiating Pharmacy. of milestone CAPSTONE The in as to leads and treatment. of the diagnosis, patients life the and providers initiate the payers. Care times providers diagnosis, to traditional care test the more negative conclusive We more establishing autoantibodies. diagnostics. a reveal of diminishes leverages was in AVISE positive that when We follow-up test lead aggressive specific is reducing Specialty had which both proud study can the with Delayed compelling. multiple new for patient. The are SLE the as for and AVISE the our results, view for X tested early, the dossier traditional need those By patients, quality Lupus find test AVISE The irreversible current and optimistic study visits payers treatment sources the outcome patients major advantage able standard-of-care. thousands to approach published ANA, with patients exemplifies lupus well comparing burden to down using odds diagnosis Lupus for treatment including findings and that of fewer The found data external largest who of study period patient. follow-up and utility this months from as the rheumatologists patients who is The odds are six times compared X greater consequences that Lupus in of recently in study X increased of Journal of an as our comparative disease that times
pipeline. to update the Turning our of
health the synovial RADR their for having correct to approach. platform assess patients RADR gene arthritis. inflamed happy to time clinical joint the of we treatment of study that tissues off and using will TiGER progress, utilization. medications. announce response stands to whether rheumatoid goal kicked trial TiGER, treatment profiling care empirical in our have wait I'm The pinpoint and providers error antirheumatic extensive to to of for development stratification for is from experience Our that will biopsies for of We which important real-world expression officially an continues in accurately molecular The predict is biomarkers The certain without individually allow called step study to the biomarkers via believe study periods the be the study.
to monitoring test. Turning our SLE
urine X.X include this nephritis. SLE biomarker and looking specific for X.X will are monitor We launch are enhancing SLE it with monitor year. markers later to lupus
know, to look cause kidney we population, impacts our of XX% forward to As available. on lupus updates We which pipeline nephritis and as providing become up including lupus damage, they severe can transplant.
As now and Kamal. business the advance we our set science allow remain our we of utility us core continue new will over to assets. will turn volume the pipeline. to policies, to the that records The we and I of to strong Exagen call navigate continue current myriad advance of remains strong, our confident payer
